MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202647085591 A) filed by Astellas Pharma Inc. on July 13, 2026, for Heterocyclic Compound For Inducing Degradation Of Kras Protein.
Inventors include Morikawa, Takahiro; Imada, Sunao; Ukegawa, Naoya; Sato, Ryo; Kawaminami, Eiji; Okumura, Mitsuaki Number; Fujiwara, Yuta; Yoshinari, Tomohiro; and Nishizono, Yoshihiro.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating cancer. The present inventors have examined a compound useful as an active ingredient in a pharmaceutical composition for cancer treatment, and have completed the present invention by finding that: a heterocyclic compound represented by formula (I) and formula (I-I) has excellent an action of inducing degradation of a mutant KRAS protein and a wild-type KRAS protein, and in particular, an action of inducing degradation of a KRAS protein having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation; and said heterocyclic compound has mutant KRAS inhibition and the inhibitory activity of KRAS amplified by a wild-type KRAS gene, and in particular, inhibitory activity of KRAS having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation. The heterocyclic compound according to the present invention or a salt thereof can be used as a therapeutic agent for cancer.
Disclaimer: Curated by HT Syndication.
